Clinical trial
Anhydrovinblastine in Treating Patients With Advanced Recurrent Solid Tumors
NCT00003882 · Roswell Park Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00003882 |
|---|---|
| Title | Anhydrovinblastine in Treating Patients With Advanced Recurrent Solid Tumors |
| Official title | Phase I Dose Finding Study of Anhydrovinblastine Administered as a 1-Hour Infusion Every 3 Weeks to Patients With Advanced Solid Tumors |
| Lead sponsor | Roswell Park Cancer Institute, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | anhydrovinblastine |
| Enrollment | 10 |
| Start date | Mar 1, 1999 |
| Primary completion | Apr 1, 2000 |
| Completion | Sep 1, 2000 |
| First posted | Jan 27, 2004 |
| Last update posted | Mar 7, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: